Marc de Garidel

Marc de Garidel graduated from the École Spéciale des Travaux Publics, an engineering grandes écoles in Paris.[1][3][4] He received a business degree from the Thunderbird School of Global Management in Glendale, Arizona, US and an executive MBA from Harvard Business School in Boston, Massachusetts.[1][3][4]

In 1983, he started his career at Eli Lilly and Company, where he worked in France, the United States and Germany.[1][3]

In 1995, he joined Amgen as vice president of finance and treasury for Europe.[1][3][4] In 1998, he became vice president, corporate controller and chief accounting officer of Amgen.[1][3] In 2000, he became vice president and general manager for France, in charge of Amgen France.[1][3] In 2006, he became vice president for Southwestern Europe, including France, Spain, Belgium and Portugal.[1][3] From 2007 to 2010, he served as vice president for Southern Europe, the Middle East, Asia and Latin America at Amgen.[1][3][4]

He was chairman and chief executive officer of Ipsen from November 2010 to July 2016.[1][3][4][5]

He was also president and spokesperson for G5 santé, a lobbying group for French pharmaceutical companies, including BioMérieux, Guerbet, Ipsen, the Laboratoire français du Fractionnement et des Biotechnologies, Laboratoires Pierre Fabre, Sanofi, Stallergenes and Laboratoires Théa.[5]

Effective July 2016, de Garidel has assumed the role of Ipsen non-executive chairman and has continued to sit on the board of directors. In addition, de Garidel will advise Mayroy, the Ipsen controlling holding company.[6] Previously, he was a director of several biotechnology companies, including vice-chairman of Vifor Pharma (Switzerland) between May 2017 and 2018 (formerly Galenica), of which he was member of the board since 2015.

In early 2018, de Garidel joined Corvidia Therapeutics, a biotech company based in Waltham, Massachusetts. In April 2018, he raised a 60M series B round led by Venrock & other top tier US & Europe venture capital funds. In June 2020, after its lead asset, Ziltivekimab, was near completion of its phase 2b program, the company was acquired for $2.1B including an upfront of $725M by Novo Nordisk in one of the largest transaction of the biotech sector in the midst of the COVID-19 epidemic.[7]

De Garidel is a director of Claris Biotherapeutics since July 2020. He joined AZTherapies as chief executive officer and board member in October 2020.[8]

 France: Knight of the Legion of Honour (2008)[9]

• La Société du Médicament (2006)